LAVA Therapeutics (LVTX) Stock Price, News & Analysis

Company Overview

LAVA Therapeutics is a clinical-stage biotechnology company focused on developing next-generation immunotherapies that leverage the body’s innate gamma-delta T cells to target cancer. The company’s proprietary “Gammabody” platform is designed to engage and activate these unique immune cells through small, bispecific mini-antibodies. By harnessing the natural tumor-seeking properties of gamma-delta T cells, LAVA aims to deliver potent, targeted antitumor activity while minimizing the off-target effects often seen with conventional T-cell engagers.

The company’s lead programs include LAVA-051, currently in early-phase clinical trials for relapsed or refractory B-cell malignancies, and LAVA-1207, an investigational candidate targeting prostate-specific membrane antigen (PSMA) in prostate cancer. Both candidates are based on the same core platform but are engineered to address hematologic and solid tumor indications, respectively. In preclinical studies, LAVA’s molecules have demonstrated robust tumor cell killing, favorable tissue distribution, and a safety profile that supports their continued clinical evaluation.

Founded in 2018 as a spin-out from leading academic institutions in Belgium, LAVA Therapeutics has rapidly built a multidisciplinary team combining expertise in antibody engineering, tumor immunology, and clinical development. The company is headquartered in Ghent, Belgium, with research and development operations in both Europe and the United States. Its leadership team includes veterans from established biopharmaceutical and oncology companies, guiding LAVA’s advancement through early clinical milestones.

As LAVA progresses its pipeline through clinical stages, the company continues to explore collaborations and partnerships to expand the reach of its gamma-delta T cell engager platform. By focusing on differentiated mechanisms of action and modular design, LAVA Therapeutics aims to address unmet needs across a broad range of oncology indications and establish a new class of targeted immunotherapies.

Key Stats

• Today's Range: $1.74 to $1.74
• 50-Day Range: $1.60 to $1.81
• 52-Week Range: $1.17 to $1.83
• Volume: N/A
• Average Volume: 187,834 shs
• Market Capitalization: $45.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.37
• Consensus Rating: Reduce

Company Calendar

• Last Earnings: 11/06/2025
• Today: 5/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LVTX
• CIK: 1840748
• Web: www.lavatherapeutics.com
• Phone: 31-85-016-3100
• Fax: N/A
• Employees: 60
• Year Founded: 2016

Price Target and Rating

• Average Price Target for LAVA Therapeutics: $1.37
• High Price Target: $1.50
• Low Price Target: $1.24
• Potential Upside/Downside: -21.3%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.11 million
• Net Margins: N/A
• Pretax Margin: -450.92%
• Return on Equity: -107.63%
• Return on Assets: -35.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.27
• Quick Ratio: 12.27

Sales & Book Value

• Annual Sales: $4.99 million
• Price / Sales: 9.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.06 per share
• Price / Book: 1.64

Miscellaneous

• Outstanding Shares: 26,305,000
• Free Float: 23,806,000
• Market Cap: $45.77 million
• Optionable: Optionable
• Beta: 0.50